"Antirheumatic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that are used to treat RHEUMATOID ARTHRITIS.
Descriptor ID |
D018501
|
MeSH Number(s) |
D27.505.954.329
|
Concept/Terms |
Antirheumatic Agents- Antirheumatic Agents
- Anti-Rheumatic Drugs
- Anti Rheumatic Drugs
- Antirheumatic Drugs
- Anti-Rheumatic Agents
- Anti Rheumatic Agents
Antirheumatic Drugs, Disease-Modifying- Antirheumatic Drugs, Disease-Modifying
- Antirheumatic Drugs, Disease Modifying
- DMARD
- Disease-Modifying, Antirheumatic Second-Line Drugs
- Disease Modifying, Antirheumatic Second Line Drugs
- Antirheumatic Disease-Modifying Second-Line Drugs
- Antirheumatic Disease Modifying Second Line Drugs
- Disease-Modifying Antirheumatic Drugs
- Disease Modifying Antirheumatic Drugs
|
Below are MeSH descriptors whose meaning is more general than "Antirheumatic Agents".
Below are MeSH descriptors whose meaning is more specific than "Antirheumatic Agents".
This graph shows the total number of publications written about "Antirheumatic Agents" by people in this website by year, and whether "Antirheumatic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1996 | 1 | 0 | 1 |
1998 | 0 | 1 | 1 |
1999 | 0 | 1 | 1 |
2000 | 4 | 0 | 4 |
2001 | 1 | 0 | 1 |
2002 | 2 | 1 | 3 |
2003 | 1 | 2 | 3 |
2005 | 4 | 1 | 5 |
2006 | 1 | 2 | 3 |
2007 | 2 | 1 | 3 |
2008 | 3 | 3 | 6 |
2009 | 3 | 1 | 4 |
2010 | 5 | 0 | 5 |
2011 | 3 | 1 | 4 |
2012 | 3 | 1 | 4 |
2013 | 2 | 2 | 4 |
2014 | 4 | 0 | 4 |
2015 | 1 | 1 | 2 |
2016 | 2 | 3 | 5 |
2017 | 7 | 1 | 8 |
2018 | 5 | 5 | 10 |
2019 | 7 | 1 | 8 |
2020 | 6 | 1 | 7 |
2021 | 4 | 0 | 4 |
2022 | 5 | 0 | 5 |
2023 | 10 | 0 | 10 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antirheumatic Agents" by people in Profiles.
-
Therapeutic drug monitoring of methotrexate in patients with Crohn's disease. Aliment Pharmacol Ther. 2023 12; 58(11-12):1151-1162.
-
Real-world Comparative Effectiveness of Methotrexate-based Combinations for Rheumatoid Arthritis: A Retrospective Cohort Study. Clin Ther. 2023 09; 45(9):e177-e186.
-
Risk of incident cardiovascular events with disease-modifying anti-rheumatic drugs among adults with rheumatoid arthritis: a nested case-control study. Clin Rheumatol. 2024 Jan; 43(1):103-116.
-
Pediatric Rheumatology Care and Outcomes Improvement Network's Quality Measure Set to Improve Care of Children With Juvenile Idiopathic Arthritis. Arthritis Care Res (Hoboken). 2023 12; 75(12):2442-2452.
-
Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events. J Immunother Cancer. 2023 06; 11(6).
-
Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis. Ann Rheum Dis. 2023 07; 82(7):920-926.
-
Trajectories of disease activity in patients with JIA in the Childhood Arthritis and Rheumatology Research Alliance Registry. Rheumatology (Oxford). 2023 02 01; 62(2):804-814.
-
Hydroxychloroquine Dose and Risk for Incident Retinopathy : A Cohort Study. Ann Intern Med. 2023 02; 176(2):166-173.
-
2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases. Arthritis Care Res (Hoboken). 2023 03; 75(3):449-464.
-
2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases. Arthritis Rheumatol. 2023 03; 75(3):333-348.